News und Analysen
![Rollins Pest Control Needs to be in Your Watchlist: https://www.marketbeat.com/logos/articles/med_20230428084917_rollins-pest-control-needs-to-be-in-your-watchlist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWo4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1f422c724f75f21cae341a76bacdbecf28d1b929/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230428084917_rollins-pest-control-needs-to-be-in-your-watchlist.jpg?locale=de)
Rollins Pest Control Needs to be in Your Watchlist
You probably see those pest control vehicles rolling through your neighborhood on a regular basis, but it’s almost certain you didn’t realize there might be an investment opportunity there.
![A Top Is In For McDonald’s Corporation Stock: https://www.marketbeat.com/logos/articles/med_20230425103230_chart-mcd-4252023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjc4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--768a28e8d85fa2cf6ed21598c439657191cbe77f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425103230_chart-mcd-4252023.png?locale=de)
A Top Is In For McDonald’s Corporation Stock
McDonald’s (NYSE: MCD) Q1 results are respectable and drove the stock to a new all-time high, but this is a top for it and perhaps the fast-food industry that could impact pricing action the rest
![Can High-Yield Whirlpool Spin Higher In 2023?: https://www.marketbeat.com/logos/articles/med_20230425082618_chart-whr-4252023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN1A4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--850660416a4fdddab4ea968b48ac2adeac698d8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425082618_chart-whr-4252023.png?locale=de)
Can High-Yield Whirlpool Spin Higher In 2023?
Whirlpool Corporation (NYSE: WHR) is not an exciting name, it isn’t a growth stock, and it has headwinds in the form of slowing home sales, but it is also an attractive investment. This blue-chip
Intuitive Machines Keeps Space Exploration Ambitions Alive
Space exploration infrastructure services and machines manufacturer Intuitive Machines Inc. (NASDAQ: LUNR) already has two strikes against it right out of the gate. The stock went public through a
![Buying the Dip On Albemarle, Fundamentals Still Sound: https://www.marketbeat.com/logos/articles/med_20230423085940_albmap.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFA4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f18be1da8fa46a1cbd01074ef24ebc5377cd54bd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230423085940_albmap.jpg?locale=de)
Buying the Dip On Albemarle, Fundamentals Still Sound
Certain mining stocks are falling after the Chilean government announced its plan to change the nation's stance toward the mining industry, rightfully worrying most investors. Chile has delivered
![AutoNation's Plans are Keeping Analysts Around: https://www.marketbeat.com/logos/articles/med_20230421074036_auto-nations-preparedness-is-keeping-analysts-arou.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOG44YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--40c9b0b9310c83e8b600a68511bea1e4ee8471f8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230421074036_auto-nations-preparedness-is-keeping-analysts-arou.jpg?locale=de)
AutoNation's Plans are Keeping Analysts Around
The vehicle market for Americans has been a nightmare for the past two quarters, and it is likely moving onto three. As low rates and cheap loans pushed inventory for new vehicles toward
![American Express Growth Riding On Joyful Consumer Spending: https://www.marketbeat.com/logos/articles/med_20230420110753_american-express-riding-on-joyful-consumer-spendin.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODM4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbb399961a1dcc9431cdbf072a3253b2a1810555/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230420110753_american-express-riding-on-joyful-consumer-spendin.jpg?locale=de)
American Express Growth Riding On Joyful Consumer Spending
Consumer spending usually follows close behind when the economic cycle swings from expansion to contraction. As discretionary and corporate spending increases, American Express (NYSE: AXP) is able
![Reliance Steel Going For New Highs And Record Profits: https://www.marketbeat.com/logos/articles/med_20230412081019_reliance-steel-going-for-new-highs-and-record-prof.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlhzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--75bd9e0a72c2740b61602ef8fa56fd507353d17e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230412081019_reliance-steel-going-for-new-highs-and-record-prof.png?locale=de)
Reliance Steel Going For New Highs And Record Profits
There are a few foundational materials that make our world go round, money is not one of them, but it sure does buy them all. Vaclav Smil, a renounced Czech scientist, wrote in his book "How the
![Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher: https://www.marketbeat.com/logos/articles/med_20230411111847_chart-tlry-4112023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjNzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5b874806835c1804583941f90cdf2baf500fa84e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411111847_chart-tlry-4112023.png?locale=de)
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
Tilray Brands (NASDAQ: TLRY) reported a mixed quarter and a deal to acquire HEXO that sent the market moving lower. While the news is less than spectacular, there are some takeaways for
![Moderna: Europäische Arzneimittelagentur erteilt für MRNA-4157/V940, einen personalisierten MRNA-Prüfimpfstoff gegen Krebs, in Kombination mit Keytruda(R) (Pembrolizumab) den Status eines prioritären Arzneimittels (PRIME) für die adjuvante Behandlung: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna: Europäische Arzneimittelagentur erteilt für MRNA-4157/V940, einen personalisierten MRNA-Prüfimpfstoff gegen Krebs, in Kombination mit Keytruda(R) (Pembrolizumab) den Status eines prioritären Arzneimittels (PRIME) für die adjuvante Behandlung
Europäische Arzneimittelagentur erteilt für MRNA-4157/V940, einen personalisierten MRNA-Prüfimpfstoff gegen Krebs, in Kombination mit Keytruda(R) (Pembrolizumab) den Status eines prioritären
![Moderna: MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stag: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna: MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stag
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for
![Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
- Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments
![Moderna finalisiert Abkommen mit Regierung von Republik Kenia hinsichtlich Errichtung von mRNA-Fertigungsanlage: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna finalisiert Abkommen mit Regierung von Republik Kenia hinsichtlich Errichtung von mRNA-Fertigungsanlage
- Anlage soll Kenia und afrikanischem Kontinent Zugang zu mRNA-Impfstoffen verschaffen, Gesundheitssicherheit gewährleisten und auf globalem Engagement von Moderna in Bereich von
![Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada
CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc. (NASDAQ:MRNA), a
![Chantal Friebertshäuser zu Senior Vice President, Commercial von Moderna ernannt: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Chantal Friebertshäuser zu Senior Vice President, Commercial von Moderna ernannt
Neu geschaffene Position wird für kommerzielle Bestrebungen in Europa, Nahen Osten und Kanada verantwortlich sein
Cambridge (Massachusetts) / Accesswire / 20. Dezember 2022 / Moderna Inc.
![Der Ausschuss für Humanarzneimittel (CHMP) der EMA empfiehlt die Anwendung von BA.1 Targeting Bivalent-COVID-19-Auffrischimpfung von Moderna bei Kindern (6–11 Jahre) in der Europäischen Union: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Der Ausschuss für Humanarzneimittel (CHMP) der EMA empfiehlt die Anwendung von BA.1 Targeting Bivalent-COVID-19-Auffrischimpfung von Moderna bei Kindern (6–11 Jahre) in der Europäischen Union
Die Empfehlung stützt sich auf klinische Daten zum bivalenten auf Omikron zugeschnittenen COVID-19-Impfstoff von Moderna, mRNA.1273.214
Die an die Omikron-Virusvarianten angepassten
![EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214
Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214
![Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA
![Moderna und Merck geben bekannt, dass mRNA-4157/V940, ein personalisierter mRNA-Krebsimpfstoff, in Kombination mit KEYTRUDA(R) (Pembrolizumab) primären Endpunkt in Phase-2b-Studie KEYNOTE-942 erreicht hat: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna und Merck geben bekannt, dass mRNA-4157/V940, ein personalisierter mRNA-Krebsimpfstoff, in Kombination mit KEYTRUDA(R) (Pembrolizumab) primären Endpunkt in Phase-2b-Studie KEYNOTE-942 erreicht hat
mRNA-4157/V940 zeigte in Kombination mit KEYTRUDA statistisch signifikante und klinisch bedeutsame Verringerung von Risiko für Wiederauftreten der Erkrankung oder Tod im Vergleich zu
![Moderna Inc.: EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna Inc.: EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in
![Moderna Inc.: Der EMA-Ausschuss für Humanarzneimittel nimmt positive Stellungnahme an, in der die Zulassung des bivalenten, auf Omikron BA.4-BA.5 abzielenden Covid-19-Impfstoffs von Moderna empfohlen wird: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna Inc.: Der EMA-Ausschuss für Humanarzneimittel nimmt positive Stellungnahme an, in der die Zulassung des bivalenten, auf Omikron BA.4-BA.5 abzielenden Covid-19-Impfstoffs von Moderna empfohlen wird
Die positive Empfehlung folgt auf die kürzlich erfolgte Zulassung von Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), einem bivalenten Booster-Impfstoff, der sich gegen die
![Moderna Inc.: EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna Inc.: EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and older
![Moderna Inc.: Der EMA-Ausschuss für Humanarzneimittel gibt eine positive Stellungnahme, in der die Zulassung zur Verwendung von Spikevax (mRNA-1273) bei Kindern von 6 Monaten bis 5 Jahren in der Europäischen Union empfohlen wird: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Moderna Inc.: Der EMA-Ausschuss für Humanarzneimittel gibt eine positive Stellungnahme, in der die Zulassung zur Verwendung von Spikevax (mRNA-1273) bei Kindern von 6 Monaten bis 5 Jahren in der Europäischen Union empfohlen wird
Die Ankündigung folgt auf die vorherige Entscheidung des CHMP, eine positive Stellungnahme abzugeben, in der die Zulassung für den COVID-19-Impfstoff von Moderna für Kinder ab 6 Jahren
![Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022
CAMBRIDGE, MA and
![Merck und Moderna geben bekannt, dass Merck seine Option für die gemeinsame Entwicklung und Vermarktung eines personalisierten Krebsimpfstoffs im Erprobungsstadium ausübt: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHJaVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d915176f7535c860c4c3ceeeaf878c96c6a98a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/KO_LOGO_-28002-29.jpg?locale=de)
Merck und Moderna geben bekannt, dass Merck seine Option für die gemeinsame Entwicklung und Vermarktung eines personalisierten Krebsimpfstoffs im Erprobungsstadium ausübt
Die Unternehmen werden planmäßig im 4. Quartal 2022 Datenmaterial aus der laufenden Phase-II-Studie zu mRNA-4157/V940 in Kombination mit KEYTRUDA® als adjuvante Therapie beim